Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $171.47, for a total value of $514,410.00. Following the completion of the transaction, the chief financial officer directly owned 158,096 shares of the company’s stock, valued at approximately $27,108,721.12. This trade represents a 1.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Trading Up 1.6%
Shares of GILD traded up $2.68 during mid-day trading on Tuesday, reaching $170.26. The company had a trading volume of 6,280,613 shares, compared to its average volume of 6,456,805. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58. The stock has a 50 day moving average of $155.90 and a two-hundred day moving average of $142.09. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same period last year, the business earned $2.47 earnings per share. Gilead Sciences’s quarterly revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.
Institutional Trading of Gilead Sciences
A number of institutional investors and hedge funds have recently modified their holdings of GILD. Bank of Nova Scotia purchased a new position in Gilead Sciences in the second quarter worth approximately $100,056,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $55,754,000. Groupe la Francaise increased its position in shares of Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the last quarter. Baird Financial Group Inc. increased its position in shares of Gilead Sciences by 3.6% in the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock valued at $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $6,251,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on GILD. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Barclays increased their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock an “equal weight” rating in a report on Monday. Jefferies Financial Group set a $196.00 price target on shares of Gilead Sciences in a research report on Wednesday, November 4th. Zacks Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Finally, Argus set a $190.00 price objective on shares of Gilead Sciences in a research report on Thursday, November 12th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $171.63.
Read Our Latest Report on GILD
Top Gilead Sciences Stories
Here are a few of the latest stories about GILD:
- Neutral Sentiment: Gilead executives appeared at the Jefferies and UBS healthcare conferences, but the provided headlines do not identify specific new guidance or announcements that would change the investment outlook. Jefferies conference transcript
- Neutral Sentiment: Gilead completed a new Foster City research center, adding specialized laboratory capacity. This may support research over time, but the completion itself does not indicate a near-term financial impact. Research center completion
- Negative Sentiment: Barclays maintained an equal-weight/hold stance while raising its price target to $160, still below the $170.26 price cited in the stock-performance information. That gap highlights valuation risk after GILD’s strong run. Barclays rating
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Articles
- Five stocks we like better than Gilead Sciences
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
